Adams Diversified Equity Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

Adams Diversified Equity Fund’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-91,200	Closed	-$13.9M	–	117
2021 Q1	$13.9M	Hold	91,200	–	–	0.6%	62
2020 Q4	$14.2M	Hold	91,200	–	–	0.64%	59
2020 Q3	$10.4M	Hold	91,200	–	–	0.51%	74
2020 Q2	$10.2M	Buy	+91,200	New	+$9.68M	0.54%	69
2019 Q3	–	Sell	-146,700	Closed	-$19.2M	–	215
2019 Q2	$19.2M	Hold	146,700	–	–	1.02%	36
2019 Q1	$19.8M	Buy	146,700 +39,500	+37%	+$4.91M	1.09%	30
2018 Q4	$10.4M	Hold	107,200	–	–	0.64%	64
2018 Q3	$14.9M	Hold	107,200	–	–	0.74%	54
2018 Q2	$13.3M	Hold	107,200	–	–	0.71%	57
2018 Q1	$11.9M	Buy	107,200 +33,800	+46%	+$4.04M	0.65%	61
2017 Q4	$8.78M	Hold	73,400	–	–	0.47%	76
2017 Q3	$10.3M	Buy	+73,400	New	+$9.97M	0.56%	71

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Adams Diversified Equity Fund's ALXN Position: Q2 2021 in Review

Adams Diversified Equity Fund sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 91,200 shares — an estimated $13.9M sold.

Adams Diversified Equity Fund first reported a position in ALXN in Q3 2017 and held it in 12 quarters. The position peaked at $19.8M in Q1 2019. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Adams Diversified Equity Fund reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Adams Diversified Equity Fund sold 91,200 Alexion Pharmaceuticals shares in Q2 2021, an estimated $13.9M.
Adams Diversified Equity Fund first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Adams Diversified Equity Fund's Alexion Pharmaceuticals position peaked at $19.8M in Q1 2019.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Adams Diversified Equity Fund's 13F filing for Q2 2021, filed 23 Jul 2021.